Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 3Phase NA 2Phase 3 1Phase 1 1

Status

Completed 50Terminated 8Unknown 3Recruiting 2Withdrawn 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasms 57Breast Neoplasms 52Leukemia, Myeloid, Acute 40Carcinoma, Non-Small-Cell Lung 40Lymphoma 35Pancreatic Neoplasms 30Leukemia, Lymphocytic, Chronic, B-Cell 30Leukemia 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Neoplasm Metastasis 27Ovarian Neoplasms 25Multiple Myeloma 25Lymphoma, Non-Hodgkin 25Recurrence 24Lung Neoplasms 23Melanoma 22Lymphoma, Large B-Cell, Diffuse 21Prostatic Neoplasms 20Glioblastoma 20Brain Neoplasms 19Colorectal Neoplasms 18Lymphoma, Follicular 17Squamous Cell Carcinoma of Head and Neck 16Sarcoma 16Lymphoma, B-Cell 15Lymphoma, Mantle-Cell 14Myelodysplastic Syndromes 13Urinary Bladder Neoplasms 12Lymphoma, B-Cell, Marginal Zone 12Glioma 12

Interventions

Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Withdrawn × Leukemia, Myeloid, Accelerated Phase × Clear all
NCT03414450 2018-10-25

Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies

EDDC (Experimental Drug Development Centre), A*STAR Research Entities

Phase 1 Withdrawn
Other hematologic neoplasm

Leukemia, Myeloid, Accelerated Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡